BMG is set to launch its new stemcell technology for cancer patients in the US in the second half of this year.
The company, which has a plant in South Carolina that produces stem cells for medical research, said it will partner with the Biotechnology Industry Organization (BIO) to develop a novel technology that could enable stem cells to be extracted from cancer patients and used to treat them.
The new technology will be called the Bio-Stem Cell Treatment, which is designed to mimic the process used to create stem cells in a lab.
The stem cells are then injected into the body of a cancer patient to treat the disease.
Bayer will work with the BIO to bring the technology to the US, and will work on commercialization in collaboration with two companies: Biostem and BioTek.
The BIO said in a statement that Bayer will work closely with BioTec to explore the commercial opportunities and the potential of the technology.
“This is a great example of a company making the leap forward from research to commercialization, and we are thrilled to partner with them on this exciting project,” said Jim Hildebrand, vice president and general manager of the company.BMG said it would use the new technology in conjunction with Bio-Tec and Biostech to create new treatments for cancer.BMI also announced that it had secured an $8 million investment from GE Capital to support stem cell research at its plant in Columbia, South Carolina.
“We are very excited about our partnership with BMG to bring stem cell technology to market,” said Jodie Hildebrant, director of the Biosciences Research and Development Center at BMG.
“We believe the new biotechnology platform developed by BMG and Biotechnology Industries will allow us to accelerate our research on stem cells, develop novel treatments for human cancers, and accelerate the development of new therapies.”BMG has also recently developed a novel stem cell treatment that uses its own proprietary stem cell protein, which could be used to produce new stem cells.